IMR Press / CEOG / Volume 38 / Issue 3 / pii/1630542838932-1840170095

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with recurrent miscarriage
Show Less
1 Department of Obstetrics and Gynecology, Adnan Menderes University, Aydın
2 Department of Obstetrics and Gynecology, Cine State Hospital, Aydın
3 Department of Biochemistry, Adnan Menderes University, Aydın (Turkey)
Clin. Exp. Obstet. Gynecol. 2011, 38(3), 228–231;
Published: 10 September 2011
Abstract

Aim(s): The present study aimed to discover whether there is an association between thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels and recurrent miscarriage (RM). In particular, TAFI antigen levels of women with RM were compared with those of a control group of women with previous uncomplicated pregnancies. Method(s): Group 1 comprised 48 women with RM, defined as the occurrence of two or more fetal losses before 20 weeks of gestation. Group 2 (the control group) was made up of 40 women who had undergone at least two healthy pregnancies and had no history of miscarriage. Group 1 was then stratified in to two groups according to the number of pregnancy losses and group 1A (2 pregnancy losses) consisted of 22 women whereas group 1B (three or more pregnancy losses) consisted of 26 women. Results: No difference was observed with regard to serum TAFI antigen levels between groups 1 and 2. There was also no statistical difference in serum TAFI antigen levels between group 1A and group 1B. Conclusion: The findings of the current study indicated that TAFI antigen levels are not associated with RM. Further multi-centric research with more subjects is needed to better evaluate the role of TAFI in RM.
Keywords
Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen
Recurrent miscarriage
Share
Back to top